MARATTO

article · Scientific Reports

Design of a multiepitope immunotherapy for fish allergy

Abstract

Fish allergy is a significant global health concern and often leads to persistent and potentially severe hypersensitivity reactions. The molecular heterogeneity of fish allergens poses challenges for developing broadly applicable immunotherapies. In this study, an integrated immunoinformatics pipeline was used to design a multi-epitope vaccine construct targeting three major fish allergens: parvalbumin, enolase, and aldolase. Predicted B-cell and T-cell epitopes were screened for immunogenicity, non-allergenicity, and lack of toxicity, and the selected peptides were assembled into a 432-amino acid chimeric construct using rationally chosen linkers to facilitate antigen processing. Computational analyses predicted the construct to exhibit favorable physicochemical properties, including stability, solubility, and a broad theoretical population coverage. Docking and molecular dynamics simulations suggested a potential interaction with Toll-like receptor 4, offering preliminary insight into possible innate immune engagement. As these findings are entirely in silico, they represent a theoretical framework; experimental validation is necessary to determine the construct's biological behavior, safety, and immunological relevance.

Research topics

  • vaccines and immunoinformatics approaches
  • Food Allergy and Anaphylaxis Research
  • Immunotherapy and Immune Responses

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1038/s41598-026-39519-y

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.